R-MTX-zanbrutinib in Secondary CNS Lymphoma
NCT05398224
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
45
Enrollment
OTHER
Sponsor class
Conditions
Secondary Central Nervous System Lymphoma
Interventions
DRUG:
Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab
Sponsor
Peking University